title: The agonist SR 146131 and the antagonist SR 27897 occupy different sites on the human CCK(1) receptor.
abstract: 1-[2-(4-(2-Chlorophenyl)thiazol-2-yl) aminocarbonyl indoyl] acetic acid (SR 27897) is an effective CCK(1) receptor antagonist, while the structurally related molecule 2-[4-(4-chloro-2, 5-dimethoxyphenyl)-5-(2-cyclohexyl-ethyl)-thiazol-2-ylcarbamoyl ]-5, 7-dimethyl-indol-1-yl-1-acetic acid (SR 146131) is a highly potent and specific agonist for the same receptor. To discover how the two molecules interact with the human cholecystokinin (CCK) CCK(1) receptor, we have carried out binding and activity studies with 33-point mutated receptors. Only six mutants showed altered [3H]SR 27897 binding properties, Lys(115), Lys(187), Phe(198), Trp(209), Leu(214) and Asn(333). In contrast, numerous mutations throughout the receptor either reduced SR 146131 agonist potency, Phe(97), Gly(122), Phe(198), Trp(209), Ile(229), Asn(333), Arg(336) and Leu(356) or increased it, Tyr(48), Cys(94), Asn(98), Leu(217) and Ser(359). Only mutations of Phe(198), Trp(209) and Asn(333) affected both SR 27897 and SR 146131 binding or activity. The collated information was used to construct molecular models of SR 27897 and SR 146131 bound to the human CCK(1) receptor. The clear difference in the binding sites of SR 27897 and SR 146131 offers a molecular explanation for their contrasting pharmacological characteristics.
authors.affiliation: Sanofi-Synthelabo Recherche, Centre de Labège, Labège-Innopole, Voie No. 1, BP 137, 31676 Cedex, Labège, France. paul.gouldson@sanofi-synthelabo.com
authors.forename: P
authors.initials: P
authors.lastname: Gouldson
authors.forename: P
authors.initials: P
authors.lastname: Legoux
authors.forename: C
authors.initials: C
authors.lastname: Carillon
authors.forename: B
authors.initials: B
authors.lastname: Delpech
authors.forename: G
authors.initials: G
authors.lastname: Le Fur
authors.forename: P
authors.initials: P
authors.lastname: Ferrara
authors.forename: D
authors.initials: D
authors.lastname: Shire
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D019556:COS Cells / Q000378:metabolism; D006727:Hormone Antagonists / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007210:Indoleacetic Acids / Q000378:metabolism* / Q000494:pharmacology; D007211:Indoles / Q000378:metabolism* / Q000494:pharmacology; D008958:Models, Molecular; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D017354:Point Mutation; D011487:Protein Conformation; D017434:Protein Structure, Tertiary; D011949:Receptors, Cholecystokinin / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D013844:Thiazoles / Q000378:metabolism* / Q000494:pharmacology
chemical_list: D006727:Hormone Antagonists; D007210:Indoleacetic Acids; D007211:Indoles; D011949:Receptors, Cholecystokinin; C118846:SR 146131; D013844:Thiazoles; C080460:SR 27897